Scorecards: Quantifying Dosimetric Plan Quality in Pancreatic Ductal Adenocarcinoma Stereotactic Body Radiation Therapy

被引:4
|
作者
Rayn, Kareem [1 ,2 ]
Clark, Ryan [2 ]
Magliari, Anthony [2 ]
Jeffers, Brian [1 ]
Lavrova, Elizaveta [1 ]
Lozano, Ingrid Valencia [1 ]
Price, Michael J. [1 ]
Rosa, Lesley [2 ]
Horowitz, David P. [1 ]
机构
[1] Columbia Univ, Irving Med Ctr, Dept Radiat Oncol, New York, NY 10032 USA
[2] Varian Med Syst Inc, Palo Alto, CA 94304 USA
关键词
D O I
10.1016/j.adro.2023.101295
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: A scoring mechanism called the scorecard that objectively quantifies the dosimetric plan quality of pancreas stereotactic body radiation therapy treatment plans is introduced.Methods and Materials: A retrospective analysis of patients with pancreatic ductal adenocarcinoma receiving stereotactic body radiation therapy at our institution between November 2019 and November 2020 was performed. Ten patients were identified. All patients were treated to 36 Gy in 5 fractions, and organs at risk (OARs) were constrained based on Alliance A021501. The scorecard awarded points for OAR doses lower than those cited in Alliance A021501. A team of 3 treatment planners and 2 radiation oncologists, including a physician resident without plan optimization experience, discussed the relative importance of the goals of the treatment plan and added additional metrics for OARs and plan quality indexes to create a more rigorous scoring mechanism. The scorecard for this study consisted of 42 metrics, each with a unique piecewise linear scoring function which is summed to calculate the total score (maximum possible score of 365). The scorecard-guided plan, the planning and optimization for which were done exclusively by the physician resident with no prior plan optimization experience, was compared with the clinical plan, the planning and optimization for which were done by expert dosimetrists, using the Sign test.Results: Scorecard-guided plans had, on average, higher total scores than those clinically delivered for each patient, averaging 280.1 for plans clinically delivered and 311.7 for plans made using the scorecard (P = .003). Additionally, for most metrics, the average score of each metric across all 10 patients was higher for scorecard-guided plans than for clinically delivered plans. The scorecard guided the Conclusions: A scorecard tool can help clarify the goals of a treatment plan and provide an objective method for comparing the results of different plans. Our study suggests that a completely novice treatment planner can use a scorecard to create treatment plans with enhanced coverage, conformality, and improved OAR sparing, which may have significant effects on both tumor control and toxicity. These tools, including the scorecard used in this study, have been made freely available.& COPY; 2023 The Author(s). Published by Elsevier Inc. on behalf of American Society for Radiation Oncology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页数:7
相关论文
共 50 条
  • [21] Stereotactic Body Radiation Therapy After Surgical Resection for Locally Recurrent Pancreatic Adenocarcinoma
    Nwachukwu, C. R.
    Toesca, D. A. S.
    Pollom, E.
    von Eyben, R.
    Chang, D. T.
    Koong, A. C.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 96 (02): : E158 - E158
  • [22] Adjuvant Stereotactic Body Radiation Therapy for Resected Pancreatic Adenocarcinoma With Close or Positive Margins
    Bernard, M.
    Ling, D.
    Rwigema, J.
    Zeh, H., III
    Heron, D.
    Burton, S.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S203 - S203
  • [23] Stereotactic body radiation therapy (SBRT) combined with chemotherapy for locally advanced pancreatic adenocarcinoma
    Gurka, Marie Kate
    Kim, Christine M.
    Haddad, Nadim G.
    Carroll, John
    Charabaty, Aline C.
    Jackson, Patrick G.
    Harter, K. William
    Hwang, Jimmy J.
    Weiner, Louis M.
    Marshall, John
    Collins, Sean P.
    Pishvaian, Michael J.
    Unger, Keith Robert
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [24] Incidence and Patterns of Locoregional Failure After Stereotactic Body Radiation Therapy for Pancreatic Adenocarcinoma
    Baine, Michael J.
    Sleightholm, Richard
    Lin, Chi
    PRACTICAL RADIATION ONCOLOGY, 2019, 9 (01) : E29 - E37
  • [25] Efficacy and Safety of Reirradiation with Stereotactic Body Radiation Therapy for Locally Recurrent Pancreatic Adenocarcinoma
    Reddy, A., V
    Hill, C. S.
    Sehgal, S.
    He, J.
    Zheng, L.
    Herman, J. M.
    Meyer, J.
    Narang, A. K.
    CLINICAL ONCOLOGY, 2022, 34 (06) : 386 - 394
  • [26] Prognostic Factors for Elderly Patients Treated With Stereotactic Body Radiation Therapy for Pancreatic Adenocarcinoma
    Sutera, Philip A.
    Bernard, Mark E.
    Wang, Hong
    Heron, Dwight E.
    FRONTIERS IN ONCOLOGY, 2018, 8
  • [27] Stereotactic Body Radiation Therapy for Pancreatic Cancer
    Goodman, Karyn A.
    CANCER JOURNAL, 2016, 22 (04) : 290 - 295
  • [28] Dosimetric Impact of Liver Rotations in Stereotactic Body Radiation Therapy
    Pinnaduwage, D.
    Paulsson, A.
    Sudhyadhom, A.
    Chen, J.
    Chang, A.
    Anwar, M.
    Gottschalk, A.
    Yom, S. S.
    Descovich, M.
    MEDICAL PHYSICS, 2015, 42 (06) : 3303 - 3303
  • [29] Assessment of biological dosimetric margin for stereotactic body radiation therapy
    Kawahara, Daisuke
    Saito, Akito
    Ozawa, Shuichi
    Shiinoki, Takehiro
    Kimura, Tomoki
    Tsubouchi, Kento
    Nagata, Yasushi
    JOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS, 2020, 21 (04): : 31 - 41
  • [30] Neoadjuvant Stereotactic Body Radiation Therapy Dosimetric Parameters Predict for Pathologic Outcomes and Survival in Pancreas Adenocarcinoma
    Chen, L.
    Cao, Y.
    Narang, A.
    Cheng, Z.
    Rosati, L. M.
    Mian, O. Y.
    Robertson, S. P.
    McNutt, T. R.
    Hacker-Prietz, A.
    Herman, J. M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 96 (02): : E213 - E214